Modification of vascular tone using iNOS under the control of a radiation-inducible promoter

Gene Therapy

Volumn 7, Issue 13, 2000, Pages 1126-1131

  Worthington, J ^a   Robson, T ^a   Murray, M ^a   O'Rourke, M ^a   Keilty, G ^a   Hirst, D G ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Gene therapy; INOS; Promoter; Radiation; Tumour vasculature

Indexed keywords

COMPLEMENTARY DNA; GREEN FLUORESCENT PROTEIN; ISOPROTEIN; N(G) NITROARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PHENYLEPHRINE; VASODILATOR AGENT;

ANIMAL CELL; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD VESSEL TONE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RADIATION; RADIATION DOSE; RADIATION EXPOSURE; RAT; REPORTER GENE; TAIL ARTERY; TUMOR VASCULARIZATION; X RAY;

EID: 0033911027     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301224     Document Type: Article

References (30)

1. Kullo IJ, Simaro RD, Schartz RS. Vascular gene transfer from bench to bedside. Arterioscler Thromb Vasc Biol 1999; 19: 196-207.
2. Nabel EG et al. Recombinant fibroblast growth-factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature 1993; 362: 844-846.
3. Ohno T et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 1994; 265: 781-784.
4. Palu G et al. Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans. Gene Therapy 1999; 6: 330-337.
5. Stewart AK et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Therapy 1999; 3: 350-363.
6. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metast Rev 1990; 9: 267-282.
7. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metast Rev 1998; 17: 7-23.
8. Sherman PA et al. Purification and cDNA sequence of an iNOS from a tumour cell line. Biochemistry 1993; 32: 11600-11605.
9. Thomsen LL et al. NOS activity in human gynecological cancer. Cancer Res 1994; 54: 1352-1354.
10. Fujisawa H et al. Inducible nitric oxide synthase in a human glioblastoma cell line. J Neurochem 1995; 64: 85-91.
11. Kasahara N, Dozy A, Kan Y. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 1994; 266: 1373-1376.
12. Manome Y et al. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene. Cancer Res 1994; 54: 5408-5413.
13. Gossen M, Bujard H. Tight control of gene expression in transgenic mice by tetracyline-responsive promoters. Proc Natl Acad Sci USA 1992; 89: 5547-5551.
14. Wang Y et al. A regulatory system for use in gene transfer. Proc Natl Acad Sci USA 1994; 91: 8180-8184.
15. Burcin MM et al. Adenovirus-mediated regulable target gene expression in vivo. Proc Natl Acad Sci USA 1999; 2: 355-360.
16. Weichselbaum RR et al. Gene therapy targeted by radiation preferentially radiosensitizes tumour cells. Cancer Res 1994; 54: 4266-4269.
17. Hallahan DE et al. Spatial and temporal control of gene therapy using ionising radiation. Nature Med 1995; 8: 786-791.
18. Manome Y et al. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the EGR-1 promoter: activation by ionizing radiation or uptake of radioactive iododeoxyuridine. Hum Gene Ther 1998; 9: 1409-1417.
19. Keyse SM. The induction of gene expression in mammalian cells by radiation. Semin Cancer Biol 1993; 4: 119-128.
20. El -Deiry SW et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825.
21. Ho YS, Wang YJ, Lin JK. Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. Mol Carcinog 1996; 16: 20-31.
22. Miller N, Whelan J. Progress in transcriptionally targeted and regulable vectors for genetic therapy. Hum Gene Ther 1997; 8: 803-815.
23. Goud C et al. Cyclic GMP-independent mechanisms of nitric oxide induced vasodilation. Gen Pharmacol 1999; 1: 51-55.
24. Tzeng E et al. Expression of human inducible NO synthase in a tetrahydrobiopterin-deficient cell line: tetrahydrobiopterin promotes assembly of enzyme subunits into an active dimer. Proc Natl Acad Sci USA 1995; 92: 11771-11775.
25. Lancaster Jr JR. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc Natl Acad Sci USA 1994; 91: 8137-8141.
26. Tzeng E et al. Vascular gene transfer of the human iNOS: characterisation of activity and effects on myointimal hyperplasia. Mol Med 1996; 2: 211-225.
27. McKeown SR et al. AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo. Br J Cancer 1995; 72: 76-81.
28. Morishita K, Johnson DE, Williams LT. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem 1995; 270: 27948-27953.
29. Andes EW et al. HMEC-1 - establishment of an immortalised human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690.
30. Hirst DG et al. Upstream modification of vasoconstrictor responses in rat epigastric artery supplying an implanted tumour. Adv Exp Mod Biol 1994; 345: 411-416.